Innovative drug companies are the pioneers of new therapies. The high risk associated with new drug development, coupled with the decreasing success rate in late-stage clinical trials, necessitates a strategic approach to R&D investment. Additionally, navigating supply chain risks in a deglobalizing world requires adaptability and foresight to ensure the uninterrupted delivery of commercialized products. Identifying reliable partners for contract services is crucial for maintaining quality and supply, while establishing effective market channels is essential for reaching the target audience and achieving commercial success. As these challenges continue to shape the industry, innovative drug companies must remain agile and resourceful to overcome obstacles and drive progress in the realm of pharmaceuticals.